Cash Flow Statement

Acquisitions Amortizatization of Intangibles Amortizatization of Intangibles Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

NRX Pharmaceuticals (NRXP) Gains from Sales and Divestitures (2024)

NRX Pharmaceuticals (NRXP) has disclosed Gains from Sales and Divestitures for 1 consecutive years, with $90833.0 as the latest value for Q4 2024.

Quarterly Gains from Sales and Divestitures changed N/A to $90833.0 in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $90833.0 through Dec 2024, changed N/A year-over-year, with the annual reading at $90833.0 for FY2024, N/A changed from the prior year.
Gains from Sales and Divestitures for Q4 2024 was $90833.0 at NRX Pharmaceuticals, up from $33333.0 in the prior quarter.
The five-year high for Gains from Sales and Divestitures was $90833.0 in Q4 2024, with the low at $33333.0 in Q3 2024.